Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Comorbidities of COPD].

H Watz1, H Magnussen

  • 1Krankenhaus Grosshansdorf, Zentrum für Pneumologie und Thoraxchirurgie und Pneumologisches Forschungsinstitut am Krankenhaus Grosshansdorf.

Der Internist
|July 6, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Statins did not reduce the frequency of exacerbations in individuals with COPD and cardiovascular comorbidities in the COSYCONET cohort.

Respiratory research·2024
Same author

Midregional proatrial naturetic peptide (MRproANP) and copeptin (COPAVP) as predictors of all-cause mortality in recently diagnosed mild to moderate COPD-results from COSYCONET.

Respiratory research·2024
Same author

[Guideline for the Diagnosis and Treatment of Asthma - Addendum 2020 - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology].

Pneumologie (Stuttgart, Germany)·2021
Same author

[Group Training of Patients with Chronic Lung Diseases under Outpatient Conditions - Recommendations of the Working Group Lung Sports in Germany and the German Airways League].

Pneumologie (Stuttgart, Germany)·2020
Same author

[Group Training of Patients with Chronic Lung Diseases under Outpatient Conditions - Recommendations of the Working Group Lung Sports in Germany and the German Airways League].

Pneumologie (Stuttgart, Germany)·2020
Same author

[Technological Innovations in Pulmonology - Examples from Diagnostics and Therapy].

Pneumologie (Stuttgart, Germany)·2020
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
See all related articles

Chronic obstructive pulmonary disease (COPD) involves serious comorbidities like cardiovascular issues and weight loss, which predict mortality. Systemic inflammation likely drives these extrapulmonary effects, impacting patient outcomes.

Area of Science:

  • Pulmonology
  • Internal Medicine
  • Pathophysiology

Context:

  • Chronic obstructive pulmonary disease (COPD) frequently presents with multiple co-existing conditions.
  • Key comorbidities include cardiovascular diseases, unintended weight loss, sarcopenia (loss of fat-free mass with muscle dysfunction), osteoporosis, and depression.
  • These extrapulmonary manifestations significantly influence clinical assessment and patient prognosis.

Purpose:

  • To highlight the significant association between COPD and various comorbidities.
  • To identify key comorbidities that serve as predictors of mortality in COPD patients.
  • To underscore the clinical relevance of extrapulmonary signs in COPD management.

Summary:

  • COPD is commonly linked with comorbidities such as cardiovascular diseases, weight loss, sarcopenia, osteoporosis, and depression.

Related Experiment Videos

  • Cardiovascular issues, weight loss, and sarcopenia are identified as crucial predictors of mortality in individuals with COPD.
  • Systemic inflammation is proposed as the underlying mechanism for the development of extrapulmonary manifestations in COPD.

    • Impact:

    • Recognizing and managing comorbidities in COPD is essential for improving patient survival rates.
    • Extrapulmonary manifestations should be considered integral components of clinical evaluation for COPD patients.
    • Understanding the role of systemic inflammation may lead to novel therapeutic strategies for COPD and its associated conditions.